Testbiotech criticises lack of balance
22 March 2021 / The European Group on Ethics in Science and New Technologies (EGE), which advises the EU Commission, has published its report on New Genetic Engineering (New GE or Genome Editing). The report deals with New GE applications in humans, animals and plants. An analysis of the report carried out by Testbiotech has found that the chapter on plants lacks the necessary balance and scientific accuracy. Testbiotech has therefore criticised the EGE for presenting conclusions on risks associated with genetically engineered plants without sufficient scientific backing.
EU Parliament has again voted against further market approvals of genetically engineered plants
11 March 2021 / The EU Parliament has again voted with a huge majority against further market approvals for genetically engineered plants. Substantial gaps in the European Food Safety Authority (EFSA) risk assessment were identified. In earlier votes, EU member states also voted overwhelmingly against market approvals. Consequently, there is growing pressure on the EU Commission for much closer scrutiny of EFSA findings and applications for market approval.
Adaptation of SARS-CoV-2 virus to the immune system not purely random
25 February 2021 / Research shows that the emergence of mutations in SARS-CoV-2 are not purely random. Rather, the virus has repair and adaptation mechanisms in its genome that can accelerate the occurrence of particularly dangerous mutations. In the light of these findings, it appears that the most effective strategies to combat the pandemic are those that aim to achieve the lowest possible incidence rates.
Max Planck Society withdraws all claims covering vertebrates
19 February 2021 / Testbiotech has won an important opposition filed at the European Patent Office (EPO). A patent held by the Max Planck Society will now be changed to delete all claims covering genetically engineered vertebrates. In its original form the patent covered many different species from mice to great apes. The animals were to be genetically engineered to develop symptoms of Parkinson disease and for use in experiments.